BMJ Best Practice

参考文献

关键文献

Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2003;74(suppl 2):ii9-ii14.

Hahn AF. Guillain-Barré syndrome. Lancet. 1998;352:635-641.

Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169:382-388.

Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.

Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58:893-898.

Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(8):CD001446.

参考文章

1.  Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2003;74(suppl 2):ii9-ii14.

2.  Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2005;76:719-722.

3.  Guillain G, Barré JA, Strohl A. Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916 [in French]. Ann Med Interne (Paris). 1999;150:24-32.

4.  Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore). 1969;48:173-215.

5.  Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J. 1957;1:1384-1387.

6.  Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986;43:1150-1152.

7.  Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1997;62:529-531.

8.  Anzai T, Uematsu D, Takahashi K, et al. Guillain-Barré syndrome with bilateral tonic pupils. Intern Med. 1994;33:248-251.

9.  Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994;51:671-675.

10.  Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130-1136.

11.  Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988;51:613-618.

12.  Poropatich KO, Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr. 2010;28: 545-552.

13.  The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41:298-306.

14.  Ropper A, Wijdicks E, Truax B. Guillain-Barré syndrome. Philadelphia, PA: F.A. Davies; 1991:1-369.

15.  Hahn AF. Guillain-Barré syndrome. Lancet. 1998;352:635-641.

16.  Ropper AH, Wijdicks E, Truax B. Guillain-Barré syndrome. Philadelphia, PA: F.A. Davies; 1991:22-30.

17.  Jones HR Jr. Guillain-Barré syndrome in children. Curr Opin Pediatr. 1995;7:663-668.

18.  Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597-605.

19.  Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in GBS. Ann Neurol. 1996;40:181-187.

20.  Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57-65.

21.  Lyu RK, Tang LM, Cheng SY, et al. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry. 1997;63:494-500.

22.  Geleijns K, Emonts M, Laman JD, et al. Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol. 2007;190:127-130.

23.  Schwerer B. Antibodies against gangliosides: a link between preceding infection and immunopathogenesis of Guillain-Barré syndrome. Microbes Infect. 2002;4:373-384.

24.  Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001;56:758-765.

25.  Van Koningsveld R, Van Doorn PA, Schmitz PI, et al. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000;54:620-625.

26.  Visser LH, Van der Meche FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain. 1995;118:841-847.

27.  Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996;39:17-28.

28.  Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119:841-879.

29.  Hemachudha T, Griffin DE, Chen WW, et al. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology. 1988;38:375-378.

30.  Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169:382-388.

31.  Malkki H. CNS infections: Zika virus infection could trigger Guillain-Barré syndrome. Nat Rev Neurol. 2016;12:187.

32.  Anaya JM, Ramirez-Santana C, Salgado-Castaneda I, et al. Zika virus and neurologic autoimmunity: the putative role of gangliosides. BMC Med. 2016;14:49.

33.  Ralapanawa DM, Kularatne SA, Jayalath WA. Guillain-Barre syndrome following dengue fever and literature review. BMC Res Notes. 2015;8:729.

34.  Oehler E, Fournier E, Leparc-Goffart I, et al. Increase in cases of Guillain-Barré syndrome during a Chikungunya outbreak, French Polynesia, 2014 to 2015. Euro Surveill. 2015;20:30079.

35.  Mishra V, Harbada R, Sharma A. Fatal Guillain-Barre syndrome (GBS) in dengue. J Assoc Physicians India. 2015;63:94-96.

36.  Bandyopadhyay D, Ganesan V, Choudhury C, et al. Two uncommon causes of Guillain-Barré syndrome: hepatitis E and Japanese encephalitis. Case Rep Neurol Med. 2015;2015:759495.

37.  Simon O, Billot S, Guyon D, et al. Early Guillain-Barré syndrome associated with acute dengue fever. J Clin Virol. 2016;77:29-31.

38.  Raphaël JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(7):CD001798.

39.  Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol. 1999;100:74-97.

40.  Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.

41.  Yuki N, Yoshino H, Sato S, et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990;40:1900-1902.

42.  Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000;48:624-631.

43.  Jacobs BC, Hazenberg MP, van Doorn PA, et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis. 1997;175:729-733.

44.  Walsh FS, Cronin M, Koblar S, et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol. 1991;34:43-51.

45.  Gregson NA, Koblar S, Hughes RA. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med. 1993;86:111-117.

46.  Yuki N, Yoshino H, Sato S, et al. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve. 1992;15:899-903.

47.  Gregson NA, Jones D, Thomas PK, et al. Acute motor neuropathy with antibodies to GM1 ganglioside. J Neurol. 1991;238:447-451.

48.  Kuijf ML, Godschalk PC, Gilbert M, et al. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol. 2007;188:69-73.

49.  Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012;79:2241-2248.

50.  Shu XM, Cai FC, Zhang XP. Carbohydrate mimicry of Campylobacter jejuni lipooligosaccharide is critical for the induction of anti-GM1 antibody and neuropathy. Muscle Nerve. 2006;33:225-231.

51.  Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA. 2004;101:11404-11409.

52.  Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain. 1984;107:219-239.

53.  Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109:1115-1126.

54.  Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996;25:33-51.

55.  Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635-644.

56.  Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol. 1991;133:940-951.

57.  Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997;48:717-724.

58.  Guillain-Barré Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Neurol Sci. 2000;21:229-234.

59.  McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001;153:610-614.

60.  Roscelli JD, Bass JW, Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988. 1991;133:952-955.

61.  Lehmann HC, Hartung HP, Kieseier BC, et al. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10:643-651.

62.  US Food and Drug Administration. FDA and CDC issue alert on Menactra meningococcal vaccine and Guillain Barre syndrome. September 2005. http://www.fda.gov/ (last accessed 19 May 2016).

63.  Kinnunen E, Junttila O, Haukka J, et al. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré syndrome. Am J Epidemiol. 1998;147:69-73.

64.  Maglione MA, Gidengil C, Das L, et al. Safety of vaccines used for routine immunization in the United States. Evidence Report/Technology Assessments, No. 215. Rockville, MD: Agency for Healthcare Research and Quality; 2014.

65.  Amundson DE, Goodman JC. Hodgkin's disease in association with Guillain-Barré-Strohl syndrome: case report. Mil Med. 1983;148:512-513.

66.  Anderson NE, Rosenblum MK, Graus F, et al. Autoantibodies in paraneoplastic syndrome associated with small cell lung cancer. Neurology. 1988;38:1391-1398.

67.  Halls J, Bredkjaer C, Friis ML. Guillain-Barré syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. Acta Neurol Scand. 1988;78:118-122.

68.  Klingon GH. The Guillain-Barré syndrome associated with cancer. Cancer. 1965;18:157-163.

69.  McLeod JG, Walsh JC. Peripheral neuropathy associated with lymphomas and other reticulosis. Peripheral Neuropathy. 1984;2:2192.

70.  Mishra BB, Sommers W, Koski CL, et al. Acute inflammatory demyelinating polyneuropathy in the acquired immune deficiency syndrome (abstr). Ann Neurol. 1985;18:131-132.

71.  Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis. 1986;18:591-592.

72.  Piette AM, Tusseau F, Vignon D, et al. Acute neuropathy coincident with seroconversion for anti-Lav/HTLV-III. Lancet. 1986;1:852.

73.  Vendrell J, Heredia C, Pujol M, et al. Guillain-Barré syndrome associated with seroconversion of anti-HTLV-III. Neurology. 1987;37:544.

74.  Cornblath DR, McArthur JC, Kennedy PG, et al. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol. 1987;21:32-40.

75.  Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology. 1997;48:214-221.

76.  Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol. 2000;15:183-191.

77.  Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 Suppl:S21-S24.

78.  Van der Meche FG, Van Doorn PA, Meulstee J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol. 2001;45:133-139.

79.  Moulin DE, Hagen N, Feasby TE, et al. Pain in Guillain-Barré syndrome. Neurology. 1997;48:328-331.

80.  Wu X, Shen D, Li T, et al. Distinct clinical characteristics of pediatric Guillain-Barré syndrome: a comparative study between children and adults in northeast China. PLoS One. 2016;11:e0151611.

81.  Sakakibara R, Hattori T, Kuwabara S, et al. Micturitional disturbance in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1997;63:649-653.

82.  Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994;17:1145-1155.

83.  Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366:1653-1666.

84.  Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve. 1989;12:435-451.

85.  McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333-342.

86.  Hiraga A, Mori M, Ogawara K, et al. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology. 2003;61:471-474.

87.  Willison HJ, Veitch J, Paterson G, et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry. 1993;56:204-206.

88.  Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007;(1):CD004761.

89.  Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126:2279-2290.

90.  Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci. 1993;118:83-87.

91.  Al-Din AN, Anderson M, Bickerstaff ER, et al. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain. 1982;105:481-495.

92.  Mori M, Kuwabara S, Koga M, et al. IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. J Neurol Neurosurg Psychiatry. 1999;67:668-670.

93.  Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104-1106.

94.  Sekiguchi Y, Mori M, Misawa S, et al. How often and when Fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis? Eur J Neurol. 2016;23:1058-1063.

95.  Thompson HS. Adie's syndrome: some new observations. Trans Am Ophthalmol Soc. 1977;75:587-626.

96.  Caccavale A, Mignemi L. Acute onset of a bilateral areflexical mydriasis in Miller-Fisher syndrome: a rare neuro-ophthalmologic disease. J Neuroophthalmol. 2000;20:61-62.

97.  Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591-2625.

98.  Van Sorge NM, van der Pol WL, Jansen MD, et al. Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. Autoimmun Rev. 2004;3:61-68.

99.  Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol. 1998;44:780-788.

100.  Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29:565-574.

101.  Brown WF, Feasby TE, Hahn AF. Electrophysiological changes in the acute "axonal" form of Guillain-Barré syndrome. Muscle Nerve. 1993;16:200-205.

102.  Murray NM, Wade DT. The sural sensory action potential in Guillain-Barré syndrome. Muscle Nerve. 1980;3:444.

103.  Paradiso G, Tripoli J, Galicchio S, et al. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal. Ann Neurol. 1999;46:701-707.

104.  DiCapua DB, Lakraj AA, Nowak RJ, et al. Relationship between cerebrospinal fluid protein levels and electrophysiologic abnormalities in Guillain-Barré syndrome. J Clin Neuromuscul Dis. 2015;17:47-51.

105.  Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58:893-898.

106.  Sundar U, Abraham E, Gharat A, et al. Neuromuscular respiratory failure in Guillain-Barré syndrome: evaluation of clinical and electrodiagnostic predictors. J Assoc Physicians India. 2005;53:764-768.

107.  Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003;31:278-283.

108.  Hiraga A, Kuwabara S. Early prediction of prognosis in Guillain-Barré syndrome. Lancet Neurol. 2007;6:572-573.

109.  O'Leary CP, Veitch J, Durward WF, et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry. 1996;61:649-651.

110.  Chiba A, Kusunoki S, Obata H, et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997;745:32-36.

111.  Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006;5:1021-1028.

112.  Ropper AH, Wijdicks E, Truax B. Guillain-Barré syndrome. Philadelphia, PA: F.A. Davies; 1991:92.

113.  Barber HS. Polyradiculoneuritis (Guillain-Barré's syndrome) in East Anglia. Lancet. 1940;2:548-550.

114.  Pillay N, Oliver S. Evoke potentials in Fisher's syndrome (abstr). Can J Neurol Sci. 1984;11:341.

115.  Yuki N, Sato S, Tsuji S, et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology. 1993;43:414-417.

116.  Rajabally YA, Durand MC, Mitchell J, et al. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015;86:115-119.

117.  Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology. 1987;37:1493-1498.

118.  Ropper AH, Wijdicks E, Truax B. Guillain-Barré syndrome. Philadelphia, PA: F.A. Davies; 1991:155-160.

119.  Andersson T, Siden A. A clinical study of the Guillain-Barré syndrome. Acta Neurol Scand. 1982;66:316-327.

120.  Ropper AH, Wijdicks E, Truax B. Guillain-Barré syndrome. Philadelphia, PA: F.A. Davies; 1991:94-95.

121.  Ropper AH, Marmarou A. Mechanism of pseudotumor in Guillain-Barré syndrome. Arch Neurol. 1984;41:259-261.

122.  Kornberg AJ, Pestronk A, Blume GM, et al. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes. Neurology. 1996;47:1317-1320.

123.  Koga M, Yuki N, Hirata K. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom. J Neurol Neurosurg Psychiatry. 1999;66:513-516.

124.  Gorson KC, Ropper AH, Muriello MA, et al. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996;47:813-817.

125.  Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;2:750-753.

126.  Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62:1194-1198.

127.  Truax B. Autonomic disturbances in Guillain-Barré syndrome. Semin Neurol. 1984;4:462.

128.  Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome. Neurology. 1999;52:635-638.

129.  Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev. 2015;(4):CD009950.

130.  Burns TM, Lawn ND, Low PA, et al. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve. 2001;24:963-965.

131.  Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245-2257.

132.  Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736-740.

133.  Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009;40:890-900.

134.  Elovaara I, Apostolski S, van Doorn P, et al; EFNS. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893-908.

135.  Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(8):CD001446.

136.  McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23:347-353.

137.  French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753-761.

138.  Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;2:1296-1299.

139.  Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177-193.

140.  Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227-228.

141.  Khan F, Amatya B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med. 2012;48:507-522.

142.  Raphael JC, Masson C, Morice V, et al. The Landry-Guillain-Barré syndrome. Study of prognostic factors in 223 cases [in French]. Rev Neurol (Paris). 1986;142:613-624.

143.  Raphael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001;71:235-238.

144.  Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with GBS requiring mechanical ventilation. Neurology. 2000;54:2311-2315.

145.  Chio A, Cocito D, Leone M, et al. Guillain-Barré Syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:1146-1150.

146.  Stewart GJ, Pollard JD, McLeod JG, et al. Calcium homeostasis in immobilization: an example of resorptive hypercalcinuria. N Engl J Med. 1982;306:1136-1140.

147.  Meythaler JM, Korkor AB, Nanda T, et al. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Arch Intern Med. 1986;146:1567-1571.

148.  Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004;19:687-694.

149.  Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341:137-141.

150.  Gracey DR, McMichan JC, Divertie MB, et al. Respiratory failure in Guillain-Barré syndrome. a 6-year experience. Mayo Clin Proc. 1982;57:742-746.

使用此内容应接受我们的免责声明。